Abstract 1483P
Background
At the time of diagnosis the majority of the lung cancer (LC) patients (pts) are old and have comorbidities. These elderly pts are underrepresented in clinical trials and their therapy options are limited. For pts whose tumor expresses PD-L1 at a lower level (TPS <50% or ICS <10%) combined platinum-based chemo-/immunotherapy is the recommended first line therapy, but elderly pts are usually unfit to receive these therapies at the regular dosage. A single-agent immunotherapy might be effective in some cases, but is only approved for pts with high PD-L1 expressing tumors (TPS ≥50% or ICS ≥10%). Data about the efficacy and safety of therapy for elderly LC pts are very limited.
Methods
In our retrospective data analysis all pts older than 75 years with LC regardless of stage treated at a German certified LC center and primary LC diagnosis from 2017 until 2022 were included. Progression-free and overall survival, objective response rate, and adverse events (AEs) resulting in therapy discontinuation were assessed for pts with systemic therapy. Data of geriatric assessment and its influence on therapy were analysed.
Results
365 out of all 1.837 newly diagnosed LC pts from 2017 to 2022 were older than 75 years. Of these pts, 115 pts (31.5%) underwent primary surgery and 15 pts (4.1%) primary radiotherapy; 143 pts (39.2%) received only systemic treatment and 92 pts (25.2%) had best supportive care. 43 pts (11.8%) sufferered from small cell LC and 322 pts (88.2%) non-small cell LC. 99 pts with systemic therapy (69.2%) received combined chemo-/immunotherapy, 31 pts (21.7%) immunomonotherapy and 13 pts (9.1%) a small molecule inhibitor. 22 pts with systemic therapy (15.4%) had an ECOG performance status (PS) of 0, 80 pts (56 %) a PS of 1, 36 pts (25.1%) PS of 2 and 5 pts (3.5%) a PS of 3. All elderly pts with high PD-L1 expressing tumors received immunomonotherapy. 89 pts (90%) of 99 pts with chemo-/immunotherapy received platinum-based chemotherapy. Of these, 30 pts (30%) had to stop therapy prematurely due to AEs.
Conclusions
Many elderly pts received combined platinum-based chemo-/immunotherapy, but therapy was often prematurely stopped due to AEs. A quarter of the pts with systemic therapy had a PS of 2. Only few pts with a poor PS (2/3) were treated with monochemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Konstantinos Ferentinos.
Funding
Has not received any funding.
Disclosure
D.C.C. Christoph: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, MSD Merck, Sharp & Dohme, Novartis, Novocure, Pfizer, Roche, Sanofi, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
1489P - To investigate the differences in efficacy between immunotherapy and combined immunotherapy in elderly patients with non-small cell lung cancer
Presenter: Ye Mao
Session: Poster session 21
1490P - Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
Presenter: Mustafa Bozkurt
Session: Poster session 21
1491P - PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients
Presenter: Jeongmin Seo
Session: Poster session 21
1493P - A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results
Presenter: Tomasz Jankowski
Session: Poster session 21
1495P - Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Presenter: Ana Baramidze
Session: Poster session 21
1496P - Higher levels of CSF-1 support resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Paul Takam Kamga
Session: Poster session 21
1497P - Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
Presenter: Yawen Bin
Session: Poster session 21
1498P - HGF/MET pathway is associated with poor efficacy of Immune checkpoint inhibitors (ICIs) in advanced-stage NSCLC
Presenter: Assya Akli
Session: Poster session 21